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ABSTRACT
Clinical evidence has shown that the elderly are at a higher risk for atherosclerotic
plaque destabilization. The effect of aging on smooth muscle cells, a major cell type in
the plaque, is central to the process of disease development yet is poorly understood.
Therefore, we set out to study young and aged smooth muscle cells at the cellular level.
Various aspects of differentiation were examined, including proliferation profile and
stimulation/inhibition response, FGF receptor production and expression, and MAPK
production and activation. We found that the overall cellular production of receptor and
MAPK in smooth muscle cells remains unaffected by aging. However, the proliferation
response of aged smooth muscle cells was muted in response to stimulation by FGF-2
and inhibition by heparin. This muted response occurred in the aged cells despite their
having a higher percentage of receptor-expressing cells and experiencing elevated MAPK
activation. We conclude that age-modulated decrease in smooth muscle cell proliferation
is caused by downstream cell cycle deficiency. The higher percentage of receptor-
expressing cells and the elevated MAPK activation level in aged smooth muscle cells are
most likely resulting from a positive feedback mechanism feeding stronger mitogenic
signals into the deficient sector of the system, in an attempt to compensate for an age-
related decrease in proliferation in agd SMC. This change in proliferation potential,
along with cellular damages and dysfunctions, leads to age-modulated differentiation of
smooth muscle cells. This phenotype of aged smooth muscle cells contributes to the
atherosclerotic plaque instability which characterizes the later stage of atherosclerotic
diseases. These findings and their implications are crucial for developing more effective
future therapies.
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1. Introduction
Vascular diseases affect the full range of arterial beds including the coronary,
peripheral, and cerebral circulations. The common pathology of the different vascular
beds is atherosclerosis of the affected blood vessels. Unfortunately, current understanding
of the mechanism underlying the atherosclerotic process is inadequate for prevention and
treatment of these diseases.
1.1 Background and Significance
Taken as a whole, atherosclerosis associated diseases are the most common cause
of death and can lead to debilitating conditions such as myocardial infarction, heart
failure, strokes, and loss of limbs. Atherosclerosis, the root of vascular diseases, is a
form of chronic inflammation which starts out with deposition of lipids along the vessel
wall early in life, sometimes as early as childhood. Plaques are formed along the vessel
wall as a result of the body's inflammatory response to the fatty streaks. This process of
plaque formation usually continues as one ages, and the plaque builds up at a variable
rate depending on the individual's lifestyle and other risk factors. For instance,
individuals with high blood pressure, high cholesterol levels, diabetes, obesity, and
frequent exposure to tobacco smoke are especially susceptible to this condition. By
middle age, most individuals are usually well under way in the atherosclerotic process
and already have raised, lumpy plaque in their blood vessels. By the later stage of the
disease, the vessel integrity at the site of the plaque is disrupted and the lesions are fairly
heterogeneous on the cellular level, containing endothelial cells, vascular smooth muscle
cells, fibroblasts, and macrophages, as well as extracellular lipids and extracellular matrix
components. This process of plaque formation, including the end-stage atheroma, is
summarized in Figure 1.1. Once the atherosclerotic plaque reaches a critical threshold, it
can obstruct blood flow in part or even completely if it ruptures. At this point, blood
clots can form and break off, restricting or blocking the blood flow to vital parts of the
body and thus placing patients in danger of stroke or myocardial infarction. Interventions
must then be made to ensure the safety and well-being of the patients.
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Figure 1.1 Illustration of the plaque formation process. The evolution of the lesion is a silent process.
Early during the atheroma, inflammatory cell recruitment and lipid accumulation lead to a lipid core capped
by layers of smooth muscle cells. Aging usually witnesses the growth of the lipid core and the thinning of
the fibrous cap, rendering it friable and susceptible to rupture. Copied from [1] with minor modification.
1.2 Current State and the Problem We Are Facing
Currently, percutaneous interventions such as angioplasty and the employment of
metal stents are the most commonly prescribed form of treatment and have been met with
great success. With advancement in disease understanding and medical treatment, the
death rate from cardiovascular disease has been declining over the past decade.
However, statistics from the American Heart Association (AHA) show that morbidity
falls heavily on the elderly: about 84 percent of cardiovascular disease deaths occur in
people age 65 and older. This is due in part to the decades it takes for the clinical
manifestation to appear in a patient, even though the atherosclerotic process starts early in
life. Additionally, the elderly are the fastest-growing sector of the population according
to the Census. Combining the severity of the disease in the elderly with a growing
elderly population presents the society with the challenging long-term goal of decreasing
overall vascular mortality in a sizeable aging population.
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1.3 Importance of Aging
This challenge centers on the issue of aging, specifically its correlation to the
observed frequency and severity of the disease. Multivariate analysis has demonstrated
that aging is a risk factor for atherosclerosis, independent of cholesterol, blood pressure,
diabetes, obesity, or smoking (AHA). For instance, studies have shown that older
animals are more vulnerable and responsive toward vascular injuries [2-4]. And well-
documented observations of physiological changes in the vascular system associated with
aging have also been identified as potentially related to the accelerated atherosclerotic
process in the aged [5].
1.4 Current Shortfall
We have witnessed encouraging advancement in therapies targeting prevention
and early intervention of other non-aging risk factors such as elevated cholesterol level,
high blood pressure, diabetes, obesity, and smoking. However, therapies targeting age-
related mechanisms that accelerate the atherosclerotic process are lacking and ineffective
in comparison, because the molecular and cellular events linking age to the process of
atherosclerotic lesion formation are not as well understood.
1.5 The Role of Smooth Muscle Cells
Based on observation of the proliferation of increased smooth muscle cells (SMC)
in reaction to mechanical injury mimicking percutaneous intervention, it was initially
hypothesized that SMC proliferation, and thus the number of SMC in the lesion, is the
primary determining factor in the progression of the disease [6, 7]. Although this
phenomenon of SMC proliferation is generally agreed to contribute to the early formation
of atherosclerotic lesions, several independent sources have reported that the sites of
plaque destabilization and rupture typically contain fewer SMC [8-10]. Consequently, it
is now generally accepted that early in the lifetime of a lesion, SMC actually protect the
stability of the lesion by reinforcing the fibrous cap. (See Figure 1.1) Later on, a paucity
of SMC in lesions leads to the detrimental stage of disease where thin and otherwise
unstable fibrous caps increase the risk of rupture [11]. According to this theory, SMC
proliferation caused by vascular injury is one of the key factors for early atherosclerotic
plaque formation. Further, the decline in the ability of SMC to proliferation during later
stages of the disease is linked with the adverse process of plaque destabilization
commonly seen in the elderly [12]. Taken in aggregate, age-modulated change of SMC
content in the plaques and age-related increase in the risk of atherosclerosis support
examining the effect of aging on SMC proliferation and on reaction to environmental
stimuli.
1.6 Specific Aims
With the hope of elucidating the effect of aging on SMC, this thesis examined the
phenomenon of age differentiation of proliferation ability with a top-down design
consisting of three consecutive phases of studies focusing on proliferation, receptor, and
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signal transduction. (See Figure 1.2). The rationale behind the order of studies consists
of not only the natural order of events when SMC interact with environmental cues, but
also a progressively focused scheme going from a macroscopic to a microscopic study on
the issue of cellular aging in SMC.
Figure 1.2 Three phases of thesis research.
Ultimately, the issue centers on the phenomenon of the various forms of age
differentiation in SMC on different levels. Specifically, this the sis tested the following
hypotheses:
1) PROLIFERATION: Aged smooth muscle cells proliferate at a slower rate than
young SMC, and have a muted response to environmental stimulatory and
inhibitory cues.
2) RECEPTOR: Age- modulated FGF receptor-I down-regulation contributes to the
age-modulated decrease in proliferation by affecting the ability of aged SMC to
react to FGF-2 stimulation.
3) SIGNAL TRANSDUCTION: The difference in the level of activation of p42/p44
between young and aged SMC is responsible for the age-modulated decrease in
proliferation.
To simplify the evaluation of a complex biological environment, this thesis sought
to examine SMC in isolation. By looking at the very fundamental changes modulated by
aging in the setting of a tightly controlled environment, this research attempted to shed
13
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light on the molecular and cellular events linking the effects of aging to SMC in
particular and to the overall process of atherosclerosis at large.
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2. Proliferation Age Differentiation
2.1 Background
Hypothesis: Aged smooth muscle cells (SMC) proliferate at a slower rate than young
SMC, and have a muted response to environmental stimulatory and inhibitory cues.
Even though more recent publications and histological data have begun to show
the lack of SMC proliferation in the progression and destabilization of advanced stage
atherosclerotic lesions [8-10], there was a time when the opposite was suggested to be
true. It was believed for many years that SMC proliferation was key to atherosclerotic
lesion progression, and that this proliferation contributed to the increased instances of
vascular events in the elderly. This association of increased vascular events in the elderly
with increased SMC proliferation was supported by animal and tissue-culture
experiments.
Animal studies have shown SMC proliferation to increase after controlled
vascular injury in aged animals relative to younger animals [6]. However, it was soon
realized that even though the observations from these studies provide invaluable
information about injury response, they couldn't be taken to be true for the entire life
cycle of atherosclerotic lesions. And in fact, current histological data indicate that it is
the lack of SMC proliferation, instead of increased proliferation, that characterizes the
progression and destabilization of advanced stage atherosclerotic lesions which are
clinically manifested predominantly in the elderly [8-11].
Even though some earlier tissue-culture studies suggested an age-related increase
in SMC proliferation, a thorough examination of studies conducted thus far on comparing
aged to young SMC actually yielded opposing opinions on the effect of aging on SMC in
the context of proliferation and atherosclerotic implications. On one hand, SMC derived
from aged Fischer 344 rats from the National Institute of Aging (NIA) seem to show a
general elevated proliferation capability relative to the young counterpart [13, 14],
although it should be noted that not all rats display this behavior [15, 16]. On the other
hand, SMC derived from humans and histological data collected from humans generally
concur on an age-related decrease in SMC proliferation capability [17]. Data collected
from mice SMC also display behavior similar to human SMC [12].
Specifically, the data reported by Ruiz-Torres et al. give strong support for age-
dependent decrease in SMC activity. From the tissue-culture study of vascular SMC
isolated from human subjects, this group reported an age-related decline in the cells'
proliferation and migration ability, measured in proliferation rate and migration assay.
Regression on the data collected showed that the expected age when little or no
proliferation would be expected in SMC actually coincides with the current limit of
human lifespan. They concluded that the age-related decline in SMC activity might be
part of the biological aging phenotype [17, 18]. Liu et al., using cavernous SMC isolated
from 4-week, 1 1-week, and 28-month old rats, also observed the lowest proliferation and
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migration rate in the 28-month old rats [15]. Moon et al., using SMC isolated from aged
mice, reported decreased proliferation capacity as well [12]. The observations reported
by these groups are fairly clear in their consensus, and it is especially reassuring to note
that the age-related decrease in SMC proliferation and migration ability is reported across
different species: humans, rats, and mice.
In opposition to the above is the set of observations supporting an age-related
increase in SMC activity [13, 14]. McCaffrey et al. reported age-related increase in the
proliferation of rat SMC, along with the interesting observation that, in the presence of
heparin, the proliferation level of aged SMC is reduced to the level of young SMC [14].
Li et al.1 also reported increased proliferation and migration rate in aged rat SMC, along
with changes in cell size and cytoskeletal proteins [13]. What is important to note at this
point is that both of those groups used SMC isolated from male Fischer 344 rats from the
NIA. As such the data supporting the argument for an age-related increase seem a little
weak compared to the argument for an age-related decrease.
If one were to set aside the above contradiction for now, then taken in aggregate,
previous studies would indicate the existence of age-related physiological changes in
SMC, something akin to an age phenotype with distinct proliferation profile.
However, since SMC derived from humans generally concur on age-related
decrease in SMC proliferation capability [17], since data collected from mice SMC also
display behavior similar to human SMC, and since publications and histological data
have shown the lack of SMC proliferation in the progression and destabilization of
advanced stage atherosclerotic lesions, we decided to test the hypothesis that aged SMC
proliferate at a slower rate than young SMC and have a muted response to environmental
stimulatory and inhibitory cues.
Closely tied to this hypothesis is the clinical observation showing elderly as
actually more susceptible to atheroma development and displaying reduced vascular
repair. Together with age-related loss of proliferation capability, this actually suggests a
puzzle linking the empirical observation of decreased proliferation ability and increased
atheroma in the elderly, possibly involving a complex network of interaction involving
age-dependent receptor trafficking, signal transduction, and cell cycle regulation.
Chapter Two and Chapter Three will address the issue of age differentiation on the level
of cell receptor and intracellular signal transduction. But first, the phenomenon of age-
modulated cellular proliferation must be explored in detail.
Specifically, this chapter sought to first validate this age-related change in
proliferation. In addition, this chapter also sought to examine, side by side, the aged and
young SMCs' ability to react to stimulatory and inhibitory cues.
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2.2 Materials and Method
2.2.1 Cell Culture
To investigate the potential age differentiation of the proliferation potential, SMC
derived from the aorta of young (2 month) and aged (30 month) Brown Norway Rats
from the National Institute of Aging were used for this thesis research. All cells were
confirmed for smooth muscle identity by indirect immunofluorescence staining with anti-
alpha SMC actin antibody.
Cells were maintained in Dulbecco's Modified Engle Media (DMEM) containing
100 units per milliliter of penicillin, 100 ug/ml of streptomycin (Invitrogen, Carlsbad,
CA), and 10% fetal bovine serum (FBS) (Hyclone, Logan, Utah), here after referred to as
growth media. Cell cultures were maintained undisturbed in a humidified environment of
an incubator at 37'C with 10% CO 2 . The cell line was continued with change of medium
every two to three days and passaged periodically. All cells used in experiments were
from passage 3 to passage 7.
2.2.2 Serum-level Proliferation Assay
Serum-level proliferation assays were conducted in 12-well tissue culture plates
(BD Biosciences, San Jose, CA). After plating, cells were incubated in growth media for
3 days, followed by starvation in 0.1% FBS media for 2 days. Seeding density of young
and aged SMC were adjusted such that, at the end of the starvation period, cell density
was comparable in the two groups. At the end of the starvation period, referred to as day
0, starvation media was removed, and cells were changed into the appropriate serum-
level groups: 1%, 5%, 10%, and 20% FBS in DMEM. Cell counts were performed on
days 0, 3, 5, 7, and 9. Media was changed once during the assay on day 5. On the day of
cell counting, cells were trypsinized after physiological balance solution (PBS) rinsing,
and cell numbers were determined using a Coulter Counter (Beckmen Coulter, Fullerton,
CA). Triplicate samples were obtained for each data point on each day at each serum
level, for young and aged SMC alike.
2.2.3 Inhibition Study: Heparin Dosage Response
Heparin dosage response was conducted in 6-well tissue culture plates (Falcon).
Cells were seeded at a density of 30,000 cells/well. After plating, cells were incubated in
growth media for 1 day, followed by starvation in 0.1% FBS media for 1 day. At the end
of the starvation period, referred to as day 0, starvation media was removed, and cells
were either changed into control group of 10% FBS in DMEM or into the appropriate
treatment groups with the following heparin concentrations: 0.1, 1, 10, 50, and 100 ug/ml
in 10% FBS in DMEM. Cell counts were performed on days 0, 3, 5, and 8. Media was
changed once during the assay on day 4. On the day of cell counting, cells were
trypsinized after rinsing with physiological balance solution (PBS), and cell numbers
were determined using a Coulter Counter. Triplicate samples were obtained for each data
point on each day at each serum level, for young and aged SMC alike.
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2.2.4 Stimulation Study: FGF-2 Dosage Response with PDGF
Fibroblast growth factor-2 (FGF-2) dose response was conducted in 6-well tissue
culture plates (Falcon). Cells were seeded at a density of 15,000 cells/well. After
plating, cells were incubated in growth media for 1 day, followed by starvation in 0.1%
FBS media for 1 day. At the end of the starvation period, referred to as day 0, starvation
media was removed, and cells were either changed into control group of 1% FBS in
DMEM or changed into the appropriate treatment groups at the following growth factor
concentrations: 5, 10, 20, and 50 ng/ml of FGF-2, and 10 ng/ml of platelet-derived
growth factor (PDGF) in 1% FBS in DMEM. Cell counts were performed on day 0, 3, 5,
and 8. Media was changed once during the assay on day 4. On the day of cell counting,
cells were trypsinized after rinsing with physiological balance solution (PBS), and cell
numbers were determined using a Coulter Counter. Triplicate samples were obtained for
each data point on each day at each serum level, for young and aged SMC alike.
2.2.5 Statistical Analysis
Student's t-test with Bonferroni adjustment was employed to ensure against
falsely significant differentiation between the young and aged SMC, using alpha of 0.05
before the adjustment.
2.3 Results
2.3.1 Serum-level Proliferation Assay: impaired proliferation capability observed
in SMC isolated from aged rats under different serum conditions.
To measure and compare the proliferation potential of young and aged SMC,
proliferation rate, measured as the number of cells per well, was tracked as a function of
serum levels over the span of 9 days.
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Figure 2.1 Young and Aged SMC proliferation response to different serum levels. Both graphs are plotted
on the same vertical scale for clearer illustration of impaired proliferation capability in SMC isolated from
aged rats. Data points are presented as mean + SD of triplicate samples. A: Proliferation profile of young
SMC showing serum stimulation of proliferation. In the data labels, "Y" designates young rats while the
number designates the serum level in percent. (p <0.04 for comparison between different serum levels,
with the exception of day 9's Y1O and Y20) B: Proliferation profile of aged SMC showing serum
stimulation of proliferation. In the data labels, "A" designates aged rats while the number designates the
serum level. (p < 0.01 for comparison between different serum level, with the exception of day 3's A10
and A20).
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The growth assay for young SMC as a function of different serum levels shows a
classic exponential proliferation profile for serum levels of 5%, 10%, and 20%. (See
Figure 2. 1A). Additional serum led to more proliferation on any given day, for the range
of serum levels administered. Additionally, increasing the serum level from 1% to 5%
led to a considerable increase in proliferation, which is also true for increasing the serum
level from 5% to 10%. However, going from 10% to 20% led to diminishing increase in
proliferation, indicating the beginning of saturation of the serum's ability to stimulate
additional proliferation in young SMC.
The growth assay for aged SMC as a function of the same serum levels shows a
more subdued and linear proliferation profile. (See Figure 2.1B). The classic
exponential growth pattern is not observed. Like young SMC, more serum level led to
more proliferation. However, unlike young SMC, the growth curve of aged SMC at 20%
serum level showed no hint of saturation yet.
The null hypothesis for our statistical analysis was that young and aged SMC
proliferated at the same rate, which would lead to comparable cell count. On any given
day when cells were counted, any pairs of data points were evaluated for significant
comparison. By day 3 and onward, aged-modulated decrease in proliferation ability was
shown to be statistically significant, supporting the hypothesis of an age-modulated
decrease in proliferation in SMC, with the exception of day 3's A10 and A20 and day 9's
YIO and Y20.
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Figure 2.2 Young vs Aged SMC proliferation differentiation at 4 different serum levels. Impaired
proliferation capability was observed in SMC isolated from aged rats. All four graphs are plotted on the
same vertical scale as Figure 2.1 for clearer illustration. In the data labels, "Y" designates young rats, "A"
designates aged rats, and the number designates the serum level. Data points are presented as mean ± SD of
triplicate samples. A: Proliferation differentiation at 1% serum. B: Proliferation differentiation at 5%
serum. C: Proliferation differentiation at 10% serum. D: Proliferation differentiation at 20% serum.
The four graphs of young versus aged SMC proliferation differentiation present
the data in a way which accentuates the difference in proliferation rate between young
and aged SMC at each of the four serum levels. (See Figure 2.2). The four graphs share
a common vertical scale for the purpose of clear comparison. Clearly, aged SMC always
proliferate at a slower rate than that of young SMC, as indicated by the decrease of
proliferation capability in aged SMC relative to the young for all serum levels after day 3.
Having established this age-differentiation in proliferation rate, Figure 2.3 summarizes
how much more proliferative young SMC were relative to aged SMC on each of the days
when samples were counted, at the different serum levels. Age-modulated differentiation
was not obvious on day 3. 10% serum witnessed the most drastic fold difference between
young and aged SMC proliferation, reaching as high as a 3-fold increase in young SMC
by day 9. 20% serum, on the other hand, witnessed not as drastic a fold difference, which
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is largely attributed to the fact that young SMC are reaching the limit of how fast they
can proliferate at this serum concentration.
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Figure 2.3 Ratio of young vs aged SMC proliferation. Each young and aged SMC data pair were divided
to yield this representation of fold increase in young SMC proliferation at each of the serum levels
administered on each date.
The above clearly illustrates that, for the same serum level, aged SMC is much
less responsive than its young counterpart in terms of proliferation capability in reaction
to serum stimulation. Having established differential proliferation profiles for aged and
young SMC, the next question of interest is to explore whether there exists an age-
dependent difference in the ability of SMC to react to anti-proliferative and proliferative
agents.
2.3.2 Inhibition Study: Heparin Dosage Response: aged SMC are less responsive
than young SMC to heparin inhibition, suggesting age-modulation of the
ability of SMC to ability to react to anti-proliferative agents.
Heparin is a gold-standard inhibitor of vascular SMC and we used heparin to
answer the question of whether the anti-proliferative effect of growth inhibitors on SMC
also experience a decrease as SMC ages. We compared the heparin dosage response
between young and aged SMC and explored the question of potential age-modulated
heparin reactivity. Do aged SMC experience relatively less heparin inhibition of
proliferation?
Because the assay is aimed at examining the issue of inhibition on healthy
proliferating cells, a control serum level of 10% FBS was chosen after reviewing the
results from the serum- level growth assay. Figure 2.4 presents the results of heparin
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inhibition over time for young and aged SMC with different heparin concentrations.
Because young and aged SMC grow at a different rate with the control of 10% serum, as
shown previously, a different vertical scale is used for clearer illustration.
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Figure 2.4 Heparin dosage response in young and aged SMC. The dosage responses of young and aged
SMC track inhibition of proliferation rate relative to heparin-free control as a function of different heparin
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level in the media over a period of 8 days. Data points are presented as mean ± SD of triplicate samples.
Note that the two graphs are plotted on a different vertical scale due to age-modulated decrease in the
proliferation rate of aged SMC. A: Heparin inhibition of young SMC and the effect of different dosage.
In the data labels, "Y" designates young rats while the number designates heparin concentration in ug/ml.
(P < 0.05, with the exception of day 3's Y50 and Y100 and day 8's Ycontrol and YO.1) B: Heparin
inhibition of aged SMC and the effect of different dosage. In the data labels, "A" designates aged rats
while the number designates heparin concentration in ug/ml. (Acontrol and AO. 1 are not significantly
different. P <0.05, with the exception of day 8's A50 and A100).
One must first establish that heparin does cause inhibition in young and aged
SMC, proving that the difference in cell count observed is not random. Student's t-test
with Bonferroni adjustment for multiple comparisons was conducted and reported in the
Figure caption. In general, the inhibitory effect of heparin is visible by day 3 in both
aged and young SMC; there is no apparent age-modulated delay in the growth pattern
observed, indicating the young and aged SMC react to heparin inhibition similarly from
the temporal perspective.
Heparin inhibits young SMC proliferation for the range of heparin concentrations
administered, with higher concentration causing greater inhibition. (See Figure 2.4A).
Statistical analysis has shown these differences modulated by heparin concentration to be
significant, with the exception of day 3's Y50 and Y100 pair and day 8's Ycontrol and
YO.1 pair.
Heparin also inhibits aged SMC proliferation, with higher concentration causing
greater inhibition. (See Figure 2.4B). Analysis showed significant difference between
the proliferation curve of each heparin level in young and aged SMC. However, the
difference between Acontrol and AO. 1 is not statistically significant on days 3, 5, and 8
when cells were counted. Day 8's A50 and A100 pair of comparison also yielded an
insignificant difference.
24
2000-
Ycontrol
1800-
1600-
Y 1
1400-
1200
0
E 1000-
S800-
000 Y50
400 Acontrol
A1
200 
- ----- ~ 5
0
0 2 4 6 8 10
days
Figure 2.5 Heparin dosage response in young and aged SMC on the same graph. Heparin levels selected
from Figures 2.4A and 2.4B were plotted on the same vertical scale. Data points are presented as mean+
SD of triplicate samples.
For a comparison of the effect of aging on the heparin dosage response of SMC,
Figure 2.5 shows both young and aged SMC dosage response on the same graph for
selected levels of heparin. The difference in proliferation rate is clearly demonstrated.
At this point, it should be noted that young SMC display an exponential growth pattern
while aged SMC grows much more linear in nature, again affirming the observations
made in the serum-level growth assay. Figure 2.5 also indicates the possibility that the
inhibitory effect of heparin is more pronounced in young SMC than in aged SMC,
coinciding with what we hypothesized. To examine this possibility of whether heparin
leads to greater inhibition in young SMC, the cell counts on day 8 were normalized to the
corresponding heparin-free control for a comparison of the extent of inhibition
experienced by young and aged SMC relative to control at the different heparin levels.
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Figure 2.6 Age-modulated differentiation in the extent of heparin inhibition on day 8. Young SMC can be
inhibited to a greater extent than aged SMC. Cell counts at difference heparin concentration were
normalized to the corresponding heparin -free control for a comparison of the inhibitory effect of heparin on
young and aged SMC. p* indicates very highly significant.
As hypothesized originally, there is significant age modulation of the reaction of
SMC to heparin inhibition. After normalization to the respective control, heparin causes
inhibition of proliferation to a greater extent in young SMC than in aged SMC. Statistical
analysis on the difference in heparin's ability to inhibit proliferation on young and aged
SMC has proven to be significant at concentrations of 1 Oug/ml and higher. In short, the
inhibitory effect of heparin is more pronounced in young SMC than in aged SMC for
heparin levels of 10 ug/ml and higher.
Having established the existence of a muted reaction to heparin inhibition related
to aging, the next logical step was to examine whether the incremental inhibitory effect of
heparin within the two age groups is also modulated by age. Stated differently, we have
established that a heparin concentration of 50 ug/ml led to greater inhibitory effect in
young SMC, but is there also an age-modulated decrease in the incremental inhibition
caused by raising the heparin concentration of 50 ug/ml to 100 ug/ml? Is the incremental
inhibition not as pronounced in aged SMC when going from 50 ug/ml to 100ug/ml of
heparin? Is there an age-modulated reduction in sensitivity toward incremental heparin
levels? To answer this question, the day 8 normalized cell counts were analyzed with the
null hypothesis of no incremental inhibition effect for each consecutive pair of data
points within young and aged SMC. Again, multiple comparison adjustments were taken
to insure against falsely significant results.
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By day 8, a heparin level of 0.1 ug/ml did not lead to significant incremental
inhibition of proliferation compared to heparin-free control, in young and aged SMC.
However, looking at high levels of heparin, concentrations higher than 50 ng/ml did not
lead to additional inhibition in aged SMC, suggestion that heparin saturation has been
reached at around 50 ng/ml in aged SMC. Young SMC, on the other hand, don't seem to
be operating in the saturating region even for heparin levels as high as 100 ng/ml. In fact,
there was no sign of saturation observed.
The result of the heparin-inhibition study on young and aged SMC is best
summarized in Figure 2.7, for it clearly illustrates both the extent to which SMC can be
inhibited by heparin as a function of age and the level of incremental inhibition as
heparin concentration goes up.
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Figure 2.7 Percent suppression of young and aged SMC as a function of heparin concentration on day 8.
This graph is constructed by the following formula applied to the data points from day 8: 100*(control cell
count - treatment cell count)/control cell count. The more inhibition there is by heparin, the higher the
percent of suppression. For example, a suppression of 70% at concentration X means 70% of the cell
proliferation in control is suppressed by heparin level of X ug/ml, and the cell count is only 30% of the
control cell count.
By taking the difference between control and heparin- inhibited cell count and
then normalizing this difference to control, Figure 2.7 is able to present the age-
modulation inhibitory effect of different levels of heparin on young and aged SMC in a
very insightful fashion. Two valuable pieces of information can be gained from this
graph, one having to do with the degree to which proliferation can be inhibited, the other
having to do with whether saturation effect is present. First, heparin inhibition of SMC
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proliferation is always more pronounced in young SMC than aged SMC, suggesting aged
SMC experiences muted reaction toward inhibition by heparin. In fact, heparin inhibition
of aged SMC approaches an asymptotic level where at most 40% of control can be
inhibited, and any additional heparin would not lead to further inhibition. However,
heparin inhibition of young SMC can lead to as high as 70% of control being inhibited,
possibly higher. Second, at heparin levels higher than 50 ug/ml there is no additional
inhibition in aged SMC, for saturation has been reached at around 50 ug/ml. Young
SMC, on the other hand, do not seem to be operating in the saturating region even for
heparin levels as high as 100 ug/ml. This differentiation between young and aged SMC
suggests an age-related change in saturation of inhibitory cue, where aged SMC actually
experience inhibition saturation at a much lower heparin concentration than do young
SMC.
2.3.3 Stimulation Study: FGF-2 Dosage Response: aged SMC are less responsive
than young SMC to FGF-2 stimulation of proliferation, suggesting age-
modulation of the ability of SMC to react to mitogenic agents.
Having shown an age-modulated decrease in the ability of SMC to react to
environmental inhibitory cues, the parallel question asked was, whether the mitogenic
effect of growth factor on SMC also experiences age-modulated decreases. These sets of
experiments are set up to compare the response to FGF-2 dosage between young and
aged SMC and to explore the question of potential age-modulated mitogen-reactivity. Do
aged SMC experience less FGF-2 stimulation of proliferation?
Because the assay is aimed at examining the issue of stimulation, a control serum
level of 1% FBS was chosen based on the results of the serum-level growth assay. A
range of FGF-2 concentration was administered. Platelet-derived growth factor (PDGF)
at a concentration of 10 ug/ml was also administered along with the different levels of
FGF-2. Figure 2.8 presents the results of growth factor stimulation over time for young
and aged SMC. Because young and aged SMC grow at a different rate in 1% serum as
shown previously in Figure 2.2A, different vertical scales were used for clearer
illustration purposes.
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Figure 2.8 FGF-2 dosage response in young and aged SMC. These two dosage responses track
stimulation of proliferation rate relative to growth factor-free control as a function of different FGF-2 level
in the media over a period of 8 days. PDGF level of 10 ug/ml is also administered along with the different
levels of FGF -2. Data points are presented as mean ± SD of triplicate samples. Note that the two graphs
are plotted on different vertical scales due age-modulated decrease in the proliferation rate of aged SMC.
Curves are labeled by FGF-2 level in ng/ml, with the exception of control, which has no growth factor, and
PDGF 10, which has 10 ng/ml of PDGF. A: Stimulation in young SMC at different dosages. (day 8: p <
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0.03 for comparison between all pairs of dosage) B: Stimulation in aged SMC at different dosages (day 8:
p <0.01 for comparison between aged control and aged PDGF 10 and comparison between aged control and
any of the aged FGF-2 dosages. However, no significant differentiation exists amongst the different FGF -2
dosages.
First, one must establish whether FGF-2 and PDGF cause proliferation in young
and aged SMC, proving that the difference observed in the cell count is not random.
Student's t-test with Bonferroni adjustment for multiple comparisons was conducted and
reported in the figure caption. In general, the stimulatory effect was visible by day 3 in
both aged and young SMC; there was no apparent age-modulated delay in the temporal
growth pattern observed, indicating that the young and aged SMC react to stimulation at
a similar rate in the temporal perspective.
10 ng/ml of PDGF simulated both young and aged SMC proliferation, but to
different degrees. (See Figure 2.8). By day 8, the cell count of young SMC was twice
that of the aged SMC in this treatment category.
As for the stimulatory effect of the different FGF-2 concentrations, a clear pattern
emerged by day 8. On day 8, young SMC demonstrated distinct and significant levels of
proliferation for the different amount of FGF-2 added. This validated that FGF-2 does
stimulate cellular proliferation in young SMC, and the range of FGF-2 administered
resulted in levels of proliferation significantly different from each other.
As for aged SMC on day 8, the presence of FGF-2 also led to stimulation of
proliferation that is significant compared to aged control on day 8, validating that FGF-2
does indeed stimulate cellular proliferation in aged SMC also. However, in aged SMC,
FGF-2 level between 5 ng/ml and 50 ng/ml yielded cell count values in the same
neighborhood on day 8; statistical analysis showed no significant differences in cell count
among these dosage levels.
Comparing this observation in aged SMC to that of the young suggests that aged
SMC either has decreased ability to detect the different levels of FGF-2 stimulation in the
environment, or has decreased ability to translate this difference into different levels of
proliferation in actuality.
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Figure 2.9 FGF-2 dosage response in young and aged SMC on the same graph. FGF-2 levels were
selected from Figure 2.8A and 2.8B and plotted on the same vertical scale.
For comparing the effect of aging on the ability of SMC to react to FGF-2
stimulation, Figure 2.9 shows both young and aged SMC dosage response on the same
graph, for selected concentrations of FGF-2. By comparing the data points in day 8, this
figure also indicates that the possibility that stimulatory effect of FGF-2 is more
pronounced in young SMC than in aged SMC, coinciding with what we hypothesized. If
this is true, then there exists an age-modulation of the ability of SMC to react to
mitogenic agents. To examine the possibility of whether FGF-2 leads to greater
stimulation in young SMC, the cell counts were normalized to the corresponding FGF-2-
free control for a comparison of the extent of stimulation experienced by young and agd
SMC at the different FGF-2 levels.
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Figure 2.10 Age-modulated differentiation in response to FGF-2 stimulation on day 8. Young SMC can
be stimulated to a greater extent than aged SMC. Cell counts as a function of difference FGF-2
concentrations were normalized to the corresponding heparin -free control for a comparison of the
stimulatory effect of FGF-2 on young and aged SMC. (P* <0.05 for comparison of each pair of young and
aged SMC at each heparin level).
At all concentrations of FGF-2 administered, young SMC were stimulated to a
greater extent than aged SMC. This difference in the stimulatory ability of FGF-2 on
young and aged SMC was hypothesized originally and is nmw confirmed to be true.
Statistical analysis has shown it is unlikely that this age-modulated decrease in the ability
of SMC to respond to FGF-2 stimulation is due to chance. In short, the stimulatory effect
of FGF-2 is less pronounced in aged SMC than in young SMC, and our original
hypothesis is confirmed.
Having established the existence of a muted reaction to FGF-2 stimulation due to
aging, the next logical step was to examine whether the incremental stimulatory effect of
FGF-2 as its concentration went up was also modulated by age. Stated differently, it was
established that 10 ng/ml FGF-2 led to greater stimulatory effect in young SMC, but is
there also an age-modulated differentiation in the incremental stimulation caused by
raising the FGF-2 concentration of 10 ng/ml to 20 ng/ml? Is the incremental stimulation
not as pronounced in aged SMC when FGF-2 concentration is raised from 10 ng/ml to 20
ng/ml? In other words, is there an age-modulated reduction in sensitivity toward
incremental FGF-2 levels? According to Figure 2.10, such would appear to be the case,
for the stimulatory effect of FGF-2 on aged SMC quickly levels off to a value much less
than the extent of stimulation experience by young SMC.
32
The incremental stimulatory effect of FGF-2 at day 8 was found to be significant
for young SMC in the range of FGF-2 concentration administered, indicating the lack of
saturation effect at least within this range of FGF-2. However, for aged SMC, FGF-2
concentration higher than 5 ng/ml did not lead to any significant incremental stimulation
of proliferation by day 8, suggesting that saturation has been reached at around 5 ng/ml.
The result of the FGF-2-stimulation study on young and aged SMC is best
summarized in Figure 2.11. It clearly illustrates both the extent to which SMC can be
stimulated by FGF-2 as a function of age and the level of incremental stimulation as
FGF-2 concentration goes up.
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Figure 2.11 Percent stimulation of young and aged SMC as a function of FGF-2 concentration on day 8.
This graph is constructed by the following formula applied to the data points from day 8: 100* (treatment
cell count - control cell count)/control cell count. The more stimulation is caused by FGF-2, the more
positive the percent of stimulation is in addition to control. For example, percent stimulation of 80 means
the treatment group is 180 percent of the control. Thus, the vertical axis indicates percent of stimulation in
addition to control.
By taking the difference between control and FGF-2-stimulated cell count and
then normalizing this difference to control, Figure 2.11 is able to present the age-
modulation stimulatory effect of different levels of FGF-2 on young and aged SMC in a
very insightful fashion. Two valuable pieces of information can be gained from this
graph, the degree to which proliferation can be stimulated, and whether saturation effect
is present. First, FGF-2 stimulation of SMC proliferation is always more pronounced in
young than aged SMC, suggesting aged SMC experiences muted reaction toward
stimulation by FGF-2. Furthermore, FGF-2-stimulated proliferation of aged SMC
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approaches an asymptotic level of 50% proliferation in addition to control, and no more.
Young SMC, on the other hand, experience stimulation as high as 160% in addition to
control, and possibly higher. Second, the saturation level of FGF-2 is much lower in
aged SMC. A FGF-2 level higher than 5 ng/ml does not lead to substantial additioml
stimulation in aged SMC, for saturation has been reached at around 5 ng/ml, as seen in
flattening of the curve. Young SMC, on the other hand, don't seem to be operating in the
saturating region even for FGF-2 concentration as high as 50 ng/ml. In fact, no sign of
saturation was observed.
2.4 Discussion
This chapter focused on the issue of proliferation and the effect of aging on the
cellular level, specifically the implications and insights to be gained in the context of age-
related atherosclerotic plaque destabilization. The hypothesis that aged SMC proliferate
at a slower rate than young SMC has been validated.
The proliferation assay (see Figure 2.2) showed that, for the serum levels
administered, aged SMC are significantly less responsive than their young counterparts in
terms of proliferation capability. To the best of our knowledge, our group is the first to
show this differentiation in serum saturation level. This finding concurred with the age-
dependent decrease in proliferation that others have demonstrated in human, mouse, and
rat cultures. Putting this in the context of later stage atherosclerotic progression, our
findings would suggest fewer SMC in the fibrous cap of the lesions, which is consistent
with previous observations [11]. In conclusion, our findings showed that, as SMC age,
not only do they respond less to serum stimulation of growth, but the serum saturation
level also raises. What this suggests is that, to achieve the same level of proliferation as
young SMC, aged SMC would require a higher level of serum stimulation. And even
with a higher serum level, the proliferation profile would still appear distinct, for aged
SMC seem to be unable to achieve the classic exponential growth profile. Interestingly,
the linear growth profile in the aged SMC compared to that of the exponential in the
young, leading to a three-fold difference in population size by day 9 for serum level of
10% (see Figure 2.3), brings up the possibility that biological or molecular changes are
preventing the aged SMC from achieving the classic exponential proliferation profile.
Furthermore, heparin- and FGF-2-dosage studies on young and aged SMC led to
the exciting finding that aged SMC experience reduced ability to respond to inhibitory
and stimulatory cues. To the best of our knowledge, our group is the first to report this
age- modulated muted response.
The heparin inhibition study, which demonstrated age modulation of the reaction
of SMC to heparin's inhibition of proliferation, carries profound implication. In addition
to proliferating at a slower rate in comparison to young SMC, aged SMC, under the anti-
proliferative influence of heparin, are inhibited to a lesser extent than young SMC. In the
context of the complex regulatory mechanisms in the human body, this suggests that as
one ages, the SMC become less reactive to the environmental inhibitory cues that
maintain a state of balance and control. Therefore, it is possible that aging as a risk factor
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for atherosclerosis has its basis in the age-modulated changes in SMC that renders it
unable to react to environmental regulatory cues, thus introducing instability to the site of
the lesion and exposing the patient to adverse events. Exactly how this translates into the
progression of lesion destabilization is a topic for future research. However, we can
safely acknowledW the existence of age-modulated decrease in sensitivity toward heparin
inhibition, combined with an overall decrease in proliferation rate.
It is possible that, instead of being limited to heparin, this finding is a universal
phenomenon that is true for other anti-proliferative agents as well. If such were the case,
the implication of this age- modulation decrease in inhibition sensitivity would be
tremendous for therapeutical consideration. If such were the case, the argument that
lesion destabilization stems from the inability of aged SMC to be regulated properly
would become even more convincing.
The FGF-2 stimulation study, showing aged SMC to be less responsive than
young SMC to FGF-2 (see Figure 2.5), suggests that age also modulates the reaction of
SMC to FGF-2 stimulation of proliferation. Specifically, under the mitogenic influence
of FGF-2, data show that aged SMC can be stimulated to a lesser extent than young
SMC, and aged SMC experience stimulation saturation at a concentration much lower
than that of young SMC. If the heparin inhibition study were one side of the story, then
the FGF-2 stimulation study would be the other side of the story. Under both
circumstances, we have found aged SMC to be less responsive to the environmental cue
given. This reduced sensitivity is clearly illustrated by the inability of aged SMC to
differentiate between the different levels of FGF-2 administered.
As shown by the PDGF treatment group, this finding of reduced ability to react to
growth stimuli is nmt merely FGF-2-specific. This finding pushes us toward believing
that this is a universal phenomenon true for many other mitogenic agents as well.
In fact, together with insights from the heparin inhibition study, a big picture
emerges where, as a person ages, the SMC display a muted ability to react to regulatory
signals, either inhibitory or stimulatory. This implies that, as one ages, the stability in the
system achieved by the complex network of regulation gradually breaks down as SMC
changes in its ability to react to those signals of communication and control. If such were
the case, the implication of this age-modulated decrease in stimulatory sensitivity would
be tremendous for both therapy and treatment.
Altogether, the results from this chapter suggest that, for the same blood serum
level, as SMC age, their proliferation ability decreases, which concurs with the lack of
SMC proliferation in the progression and destabilization of advanced stage
atherosclerotic lesions. Furthermore, heparin and FGF-2 dosage response data point
toward the interesting phenomenon of age-modulated decrease in sensitivity toward
heparin inhibition and FGF stimulation. In short, aged SMC cannot be inhibited or
stimulated as much as young SMC. And if one were to increase the amount of those
environmental inhibitory or stimulatory agents, saturation is reached fairly quickly in
aged SMC. This age-associated muted response, along with reduced sensitivity toward
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environmental inhibitory and stimulatory cues, has profound implications for the overall
communication and stability of the system. Many of the biological activities and
regulatory mechanisms are regulated through a complex network of cytokine
communication. As SMC ages, it is highly possible that the trend toward atherosclerotic
plaque instability depends heavily on this change in sensitivity to environmental
inhibitory and stimulatory cues.
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3. Receptor Age Differentiation
3.1 Background
Hypothesis: Age-modulated FGF receptor-i down-regulation contributes to the age-
modulated decrease in proliferation by affecting the ability of aged SMC to react to FGF-
2 stimulation.
Data from the Chapter Two has demonstrated that a fundamental difference
between young and aged SMC lies in the age-modulated decrease in proliferation, both in
normal growth condition and under FGF-2 stimulation. As SMC receive mitogenic cues
from the environment, a complex cascade of signal propagation and transduction
pathways is activated intracellularly, ultimately leading to cell division and proliferation.
Results from Chapter Two would suggest that, even though the same amount of FGF-2 is
administered to young and aged SMC, somewhere in the signal transduction pathway
leading to proliferation, the strength of stimulatory signals could be weakened in aged
SMC relative to the young, thus leading to decreased proliferation. To track the possible
location of this age-related dysfunction downstream of FGF-2 stimulation, we selected a
well-understood stimulus and followed its differential downstream effect on aged and
young SMC.
We decided to use FGF-2 as our stimulator. Not only were primary data on age-
modulation of FGF-2-stimulated SMC proliferation available from Chapter Two, but also
the effect of FGF-2 on cells has been extensively studied and documented, especially in
the context of vascular diseases. Since FGF-2 is an important mitogen in the blood vessel
wall [19], tracing the steps of FGF-2 leading to different effects in young and aged SMC
is crucial for a better understanding of the atherosclerosis process as related to aging.
It is known that FGF-2 is a member of a large family of polypeptides and is
synthesized in a range of cell types, including endothelial cells, fibroblasts, SMC, and
macrophages. Its biological effects are mediated by high-affinity cell surface receptors
from the protein tyrosine kinase family. Though four different receptors have been
identified, FGF-2 and FGF receptor-I are the predominant growth factor and growth
factor receptor form in SMC [20, 21]. The FGF-2 signal transduction pathway leading to
cellular proliferation is illustrated in Figure 3.1.
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Figure 3.1 FGF-2 stimulation of proliferation. The binding of FGF-2 to its cell surface receptors is
enhanced by cell surface heparin sulfate proteoglycans, and the binding leads to activation of the surface
receptors via autophosphorylation. These receptors then convey the stimulatory signals across the cell
membrane to the inside the cell and activate RAS. In summary, RAS recruit RAF- 1, which then activate
MEK. MEK proceed to activate the mitogen-activated protein kinases (MAPK), which translocate to the
cell nucleus where they directly activate transcription factors to start transcribing the cellular DNA. FGF-2
activation can lead to a few end-point biological effects, one of which is cell proliferation. Figure copied
from [22].
FGF-2 plays an important role during the vascular injury repair process following
common procedures such as angioplasty and stent implantation. While in vivo studies
have shown that FGF-2 administration in an artery with an intact endothelial monolayer
does not elicit SMC replication, administration of FGF-2 after vascular injury denudes
the endothelium has been shown to increase SMC growth. SMC proliferation in this
context, unfortunately, often results in the formation and thickening of the neointima
during this repair process, leading to complications such as restenosis [19].
It is possible that age-modulated decrease of proliferation in aged SMC actually
reflects a weakening or dysfunction of a segment of the FGF-2 activated signal
transduction pathway. In the situation where an equal amount of extracellular stimulus
exists for young and aged SMC, weakening of any of the links in the FGF-2 activated
signal transduction pathway in aged SMC could explain the observed ultimate decrease in
proliferation.
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This chapter explores the first step of the FGF-2 signal transduction pathway and
postulates that age-modulated FGF receptor-I expression affects the ability of SMC to
react to FGF-2 stimulation. It is possible that, despite an equal amount of FGF-2 in the
environment for young and aged SMC, their ability to relay this signal further
downstream is limited by an age-modulated decrease in receptor expression. If receptor
down-regulation were a characteristic of the aged SMC phenotype, fewer receptors would
lead to a weaker signal being conveyed into the intracellular environment, which could
ultimately be responsible for the age- modulated decrease in proliferation observed.
van Neck et al. have looked at the expression of FGF-2 and FGF receptor genes in
cultured rat aortic smooth muscle cells. Their group actually detected FGF receptor-I
transcription in both young and aged cultures. Additionally, FGF receptor-I mRNA was
observed to be expressed more abundantly in aged SMC [19]. However, this group did
not look at the actual protein-level expression of the receptor of interest on the cell
surface.
Our literature search has yet to yield information on the protein level expression
of FGF receptor-I in the context of young versus aged rat SMC. This lack of information
made the question this chapter is trying to answer even more exciting in its implication.
Even though receptor level study is just a small piece of the big puzzle, it is nevertheless
an important piece, for it is the first stage of the signal transduction pathway. Exploring
this question of receptor expression brought a better understanding of the biological and
mechanistic change in the aged SMC.
3.2 Materials and Method
3.2.1 Western Blot for Total Cellular FGF receptor-1
This assay examined the amount of total cellular FGF receptor-I protein
transcribed. To ensure the cells exhibited normal growth characteristics after lysis, young
and aged SMC were plated and grown in normal growth condition of 10% FBS media
until around 60% confluence and lysed after quick and thorough PBS rinsing. To ensure
enough proteins were present, two p100 plates were pooled per sample.
The antibody for FGF receptor-I was purchased from Upstate Biotechnology
(Lake Placid, NY). Secondary antibody conjugated to horseradish peroxidase was
purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA).
Fresh lysing buffer (50 mM HEPES, 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA,
10% glycerol, 1 mM DTT, 0.4mM PMSF, 0.2mM NaF, and 0.2 mM NaOrthovanadate)
was used, and total cellular protein was extracted. The supernatant was collected after
centrifugation, and total protein content was measured by using the BCA protein assay
according to the manufacturer's instructions (Pierce, Rockford, IL). Fifty micrograms of
total cellular protein from young and aged SMC were loaded onto a 15% SDS-PAGE
(Bio-Rad, Hercules, CA) gel which was loaded into the electrophoresis apparatus (Bio-
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Rad) and run for 45 minutes at 200 volts. Kaleidoscope prestained Standard from Bio-
Rad was also loaded on the gel for visualization purposes. The proteins were then
electroblotted onto PVDF membrane (Millipore, Billerica, MA) at 100V for 1 hour.
After 1 hour blocking with 5% nonfat dried milk in TBS with 0.5% Tween, nitrocellulose
membranes were incubated in the primary antibody (1:500) with shaking. After washing,
the membranes were incubated with the secondary antibody (1:1000) for 1 hour with
gentle shaking. After washing, the membranes were then treated with the
chemiluminescence substrate (Perkin Elmer, Wellesley MA) for 1 minute, followed by
exposure to x-ray film for the proper duration in the dark for visualization of the protein
bands.
3.2.2 Fluorescence-activated Cell Sorter (FACS) for surface FGF receptor-1
The expression of FGF receptor-I on the surface of cultured SMC was detected
by using FACS technology. The same antibody for FGF receptor-I used for Western
blotting was used for FACS (Upstate Biotechnology, Lake Placid, NY). Secondary
antibody conjugated to Oregon-Green was purchased from Molecular Probes (Eugene,
OR).
Young and aged SMC were seeded at around 60% confluence and cultured in
10% FBS media for 24 h. Media was then aspirated, and the cells rinsed in PBS,
incubated in 2 mM EDTA dissociation solution for 30 min, and harvested by gentle
scraping. The cell suspension was washed and resuspended in 100 ul of solution with
primary antibody at concentration as described in product data sheet. Primary antibodies
were incubated with SMC cells for 30 min at 40C, washed, and re-suspended in 100 ul of
secondary antibody solution, and incubated for 30 min at 4'C. After immunofluorescence
labeling, cells were washed twice, fixed in 0.2 ml 1% paraformaldehyde, and analyzed in
a BectonDickinson FACScan flow cytometer. Data were analyzed using CellQuest
software (Becton Dickinson).
3.3 Results
3.3.1 Western Blot for total cellular FGF receptor-1: aged and young SMC
transcribe comparable levels of FGF receptor-1 under normal growth
conditions in culture.
Young and aged proliferating SMC were used for this experiment. The total
cellular FGF receptor-I protein transcribed under normal growth condition for young and
aged SMC is shown in Figure 3.2.
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Figure 3.2 FGF receptor-1 protein transcription level in young and aged SMC. Cells under normal growth
condition of 10% FBS were lysed after rapid and thorough PBS rinsing and Western blotted. A: Total cell
lysates were probed for FGF receptor- 1 by Western blot analysis. The young samples were performed in
quadruplicate while the aged were done in triplicate. B: Quantification of the Western data reported in
arbitrary unit (AU)
Western blotting for FGF receptor-I revealed a major band at 110 kilo-Dalton
(kDa), with two faint bands around 220 kDa and 65 kDa (not shown). The 110 kDa band
represented the intact receptor and corresponded to the largest of the receptor splicing
variants expressed by SMC [23]. The 220 kDa band was most likely made up by a trace
amount of the unreduced portion of the protein, while the 65 kDa band represented slight
degradation of the protein. To quantify the amount of protein present at the major band,
image quantification software was employed and the resulting data analyzed. Image
quantification, together with statistical analysis, showed there was no significant
difference in the level of FGF receptor-I protein in young and aged SMC under normal
growth conditions.
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The original hypothesis was that receptor down-regulation can lead to weaker
stimulation by FGF-2 in aged SMC compared to that of young SMC. Therefore, the null
hypothesis is that there is no age-modulated difference in the amount of FGF receptor-i
protein transcribed. Student's t-test with the alternative hypothesis that aged SMC
transcribe less FGF receptor-I yielded an insignificant P-value, indicating the lack of
age-modulated difference in the total cellular amount of FGF receptor-I protein
transcribed.
3.3.2 FACS on surface FGF receptor-1: aged SMC express more surface FGF
receptor-1 than young SMC under normal growth conditions in culture.
Having examined the amount of receptor protein transcribed under normal growth
condition, we next looked at the number of receptors actually expressed on the cell
surface for FGF-2 to bind to, since not all receptors transcribed are expressed on the cell
surface.
To determine whether there existed an age-dependent differentiation in the
amount ofFGF receptor-I expressed on the cell surface under normal growth conditions,
young and aged SMC were analyzed by the FACS procedure described in the method
section. To ensure greatest consistency with the data from the Western blotting, the same
monoclonal antibody used for Western blotting was also used for FACS analysis. Figure
3.3 shows the resulting distribution of positively selected cells, the cells expressing
surface FGF receptor-1, relative to the entire population, as measured by FACS. The Mi
region signifies the portion of the population positively selected for cell surface FGF
receptor-I expression.
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Figure 3.3 FACS analysis on young and aged SMC for surface FGF receptor-1. Fluorescence intensity is
expressed on the horizontal axis and cell count on the vertical axis. The MI region is drawn taking into
consideration the Gaussian distribution and signifies the portion of the population selected positive for
expressing cell surface FGF receptor-1. A: Distribution from one of the triplicate young SMC samples.
B: Distribution from one of the triplicate aged SMC samples.
Aged SMC % of positive cell geometric mean of positive cells (AU)
sample #1 63.01 450.16
sample #2 61.57 501.47
sample #3 63.03 458.16
Young SMC % of positive cell geometric mean of positive cells (AU)
sample #1 36.86 536.65
sample #2 41.74 444.15
sample #3 42.5 445.57
Table 3-1 Summary of statistical information reported by FACS. The percent of positive cell reported the
percentage of the total sample space expressing surface FGF receptor-1. The geometric mean for positive
cells reported the mean fluorescence intensity of those cells positively selected.
Clearly, aged SMC express more FGF receptor-I on their surface than young
SMC. In the samples analyzed, 62.53% ± 0.84 of the aged SMC expressed FGF receptor-
1 on average. However, this number dropped to 40.37% ± 3.06 in young SMC.
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Student's t-test with null hypothesis of no age-modulated difference and alternative
hypothesis of one-end comparison yielded a P-value indicating that the increased
percentage of FGF receptor-I expressing cells in aged SMC is very highly significant.
Having quantified the percentage of the cells expressing FGF receptor-I on their
surface, the next question asked was how many receptors were expressed on the young
and aged positively selected SMC. We felt this issue of receptor density was very
important for the following reason: knowing a cell is positively selected does not reveal
any information on whether the cell expresses five or fifty FGF receptor-1. In our test
condition, it is possible that, even though more aged SMC expressed the receptor of
interest, the receptor was actually expressed at a significantly lower density in aged SMC
than in young SMC, which definitely would impact the downstream signal transduction.
Conveniently, FACS analysis, among other information, provided the geometric
mean of the fluorescence strength on the surface of the positively-selected cells,
reflecting the amount of bounded antibody. This gave us an indication of the density of
FGF receptor-I on the surface of the positively-selected cells. For young and aged SMC,
this geometric mean was reported as 475.45 ± 53.01 arbitrary unit (AU) and 469.93 ±
27.61 AU correspondingly. Student's t-test with null hypothesis of no age-modulated
difference and alternative hypothesis of one-end comparison yielded an insignificant P-
value, indicating there is no appreciative difference in the surface FGF receptor-I density
between young and aged SMC. Thus, even though aging leads to a larger fraction of the
SMC population expressing FGF receptor-I on their cell surface, it does not alter the
actual cell surface receptor density.
3.4 Discussion
In this chapter, the levels of total cellular and surface FGF receptor-I were
examined in aged and young SMC under normal growth conditions. The original
motivation was to look at the very first step in the FGF-2 activated-proliferation pathway
for clues to the age-modulated decrease in proliferation observed in Chapter Two. We
hypothesized that age-modulated decrease in FGF receptor expression could lead to
weaker signals being transducted downstream, thus affecting the ability of SMC to react
to FGF-2 stimulation.
The combined Western blot data and FACS analysis suggested to us that aging
does not modulate the amount of FGF receptor-1 protein transcribed in SMC, nor does it
alter the density of surface receptor expression. None of those findings were in direct
opposition to what we proposed. However, contrary to our hypothesis, the FACS data
illustrated that aging does lead to a significantly larger fraction of the SMC population
expressing the surface receptor.
Viewed in conjunction with the proliferation assay from Chapter Two, which
showed aged SMC to proliferate at a slower rate under FGF-2 stimulation, the FACS
finding, in which more aged SMC were found to express surface FGF receptor -1, cannot
explain why aged SMC would experience decreased proliferation. In fact, these two
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pieces of data together revealed to us that the reason behind the eventual decrease in the
proliferation ability of aged SMC most likely lies downstream of the receptor segment of
the FGF activated-proliferation pathway.
In this chapter, the simple hypothesis of receptor down-regulation contributing to
age-modulated decrease in proliferation was shown to be false, making this phenomenon
even more complicated and interesting. The next logical step we took in search for an
answer led us further downstream in the signal transduction pathway initiated by FGF-2
stimulation.
It is important to note a realization we had at the conclusion of this chapter's
study: if the differentiation causing the eventual proliferation decrease in aged SMC
indeed took place downstream of the surface receptor level, then the phenomenon of
more receptor-expressing aged SMC could result from a feedback mechanism which tries
to compensate for the downstream decreased proliferation in aged SMC by increasing the
fraction of the SMC population that FGF-2 can readily stimulate.
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4. Signal Transduction Age Differentiation
4.1 Background
Hypothesis: The difference in the level of activation ofp42/p44 between young and aged
SMC is responsible for the age-modulated decrease in proliferation.
Abnormal proliferation and migration of SMC play an important role in the
physiopathology of the atherosclerotic process (Ruiz- Torres). As shown by the assays
conducted in Chapter Two, SMC isolated from aged rats display growth characteristics
clearly muted relative to those isolated from young rats, in proliferation rate and
sensitivity to stimulatory and inhibitory agents. Moreover, aging has been associated
with increased SMC dysfunction, as seen in the repair process after vascular injury and
atherosclerotic plaque instability [1, 11]. Taken together, age-dependent change in SMC
growth characteristics may contribute to the increased severity and prevalence of
atherosclerosis in the elderly.
SMC proliferation is a key event in the remodeling of the vessel wall and the
development of atherosclerosis [1]. Regulating this proliferation are growth factors and
G-protein coupled receptor agonists controlling gene transcription by signaling the
nucleus via mitogen-activated protein kinases (MAPK) [24]. MAPK are a family of
protein serine/threonine kinases including at least four distinct regulated groups in
mammals: extracellular signal-related kinases (ERK 1/2) or (p42/p44 MAPK), Jun
amino-terminal kinases (JNK 1/2/3), p3 8 proteins, and ERK5 [25]. MAPK are activated
by a variety of stimuli, including growth factors, cytokines, antigens, hormones, lipid
compounds, and mechanical forces. These enzymes phosphorylate different intracellular
proteins and play important roles in regulating gene expression and cell proliferation,
survival, death, motility, and differentiation [26]. The MAPK integrate multiple signals
from various second messengers, resulting in cellular proliferation or differentiation [24].
In this complex network of regulation, the p42/p44 cascade has been specifically
shown to be predominantly involved in the regulation of cell proliferation stimulated by
both growth factors and G-protein-coupled receptor agonists [27, 28]. Moreover,
p42/p44 has been reported to be activated in the arterial wall after balloon injury in
different animal models [29-32]. These findings suggested to us that p42/p44 represents
a link between vessel injury and SMC proliferation in atherosclerosis and play a key role
in the earlier stages of mitogenesis.
Studies have shown a number of growth factors, including FGF-2 and PDGF, to
stimulate the activation of p42/p44 in a variety of cell types including SMC [33-36]. As
p42/p44 is one kind of MAPK, the two terms will be used interchangeably for the rest of
the thesis. In summary, once FGF-2 activates the surface FGF receptor-1, there is a
sequential cascade of protein kinases consisting of RAS, RAF, MEK, and MAPK. (See
Figure 3.1). Once activated, MAPK translocate to the cell nucleus and regulate the
expression of transcription factors, thus leading to cellular proliferation and other cellular
functions [22, 27, 28].
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Although FGF-2, the stimulatory agent selected for this study, is known to
simulate proliferation in SMC via MAPK, the cellular and molecular mechanisms behind
the phenomenon of age-modulated SMC proliferation is unclear, specifically with regard
to role of MAPK activation. Therefore, after Chapter Three studied SMC age
differentiation on the receptor level, this chapter studies the underlying effect of aging on
SMC mitogenesis associated with the intracellular level activation of MAPK by FGF-2.
Specifically, the levels of p42/p44 MAPK transcription and activation, as a measure of
the baseline protein expression level and as a measure of the mitogenic signal
translocated to the cellular nucleus, were evaluated in young and aged SMC at different
time points post FGF-2 stimulation. The data from this chapter provide an intracellular
signal transduction level understanding of the age-differentiation in SMC which, together
with the data from the previous two chapters, presents a useful picture of the effect of
aging on SMC.
4.2 Materials and Method
4.2.1 Western on MAPK and phospho-MAPK
Sub-confluent young and aged SMC under normal growth conditions were placed
into starvation medium, and growth-arrested for 24 hours. At time zero, SMC were
either lysed, or changed into 10 ug/ml of FGF in 1% FBS media then lysed at the
corresponding time points: 5 minutes, 1 hour, 3 hours, and 5 hours after FGF-2
stimulation.
Western blotting was conducted as previously described. The antibody for
MAPK was used to probe for the level of MAPK protein transcribed in young and aged
SMC, while the antibody for phospho-MAPK was used to probe for the actual level of
MAPK activation. Both antibodies were purchased from Cell Signaling Technology
(Beverly, MA). Secondary antibody conjugated to horseradish peroxidase was purchased
from Santa Cruz Biotechnology Inc (Santa Cruz, CA).
4.3 Results
4.3.1 Western blot for p42/p44 MAPK: aged and young SMC transcribe
comparable level of p42/p44 MAPK before and at different time points post
FGF administration.
p42/p44 MAPK-specific antibody was used as a probe to compare the level of
MAPK transcribed in young and aged SMC. Western blot analysis results are shown in
Figure 4.1.
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Figure 4.1 Western blots for p42/p44 expression as a function of age and FGF-2 stimulation duration. A
and B: Western blot analysis performed with p42/p44 specific antibody, assessing potential differentiation
(magnitude and temporal) in MAPK level between young (left) and aged (right) SMC. C: Quantification
of MAPK expression level. AU stands for arbitrary unit. Statistical analysis showed no significant age and
temporal modulation of MAPK transcription level in the data obtained (p>0.05, n=3 for all except young 0
min, I hr, and 3 hr where n=2).
The FGF-2 dosage response from Chapter Two showed aged SMC to demonstrate
a proliferation profile muted relative to that of the young SMC when stimulated with
lOng/ml of FGF-2 in 1% FBS media. The same stimulation is repeated here, but instead
of tracking proliferation, we looked at intracellular MAPK expression. We found no
significant difference in the young and aged MAPK levels at time zero and after the
administration of FGF-2, indicating the lack of temporal and age modulation of MAPK
level by FGF-2 in young and aged SMC. Age had no bearing on the amount of MAPK
expressed, and administration of FGF-2 did not lead to any up- or down-regulation of the
level of MAPK protein transcribed, at least for the time frame examined. Quantification
software and statistical analysis were employed, confirming the lack of differentiation
between young and aged SMC p42/p44 MAPK level, constitutively and under
stimulation.
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4.3.2 Western blot for phospho-p42/p44 MAPK: aged and young SMC express
distinct pattern of p42/p44 MAPK activation constitutively and at different
time points post FGF-2 administration.
Having used p42/p44 MAPK-specific antibody to compare the level of MAPK
transcribed in SMC before and at different time points post FGF-2 administration, we
examined the actual level of phosphorylated MAPK, as an indication of the actual level
of enzyme activation.
Phospho-p42/p44 MAPK-specific antibody was used to probe for the level of
MAPK activation in young and aged SMC in control constitutively and at different time
points post FGF-2 administration. Western blot results are shown in Figure 4.2.
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Figure 4.2 Western blots for phospho-p42/p44 expression as a function of age and FGF -2 stimulation
duration. MAPK activation as a function of age and FGF -2 stimulation duration showed distinct age-
modulation between and aged SMC. A and B: Western blot analysis performed with phospho-p42/p44
specific antibody, assessing potential differentiation (magnitude and temporal) in MAPK activation
between young (left) and age (right) SMC. C: Quantification of p42/p44 MAPK activation. p<0.05 with
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the exception of young at 5min and lhr and aged at 5 min. n=3 for all except young 0 min, I hr, and 3 hr
where n=2.
Quantification and analysis of the Western blots found the constitutive level of
p42/p44 MAPK activation to be indeed much higher in aged SMC than in young.
Despite this constitutive difference, at 5 min after FGF-2 stimulation aged and young
SMC expressed comparable levels of phospho-MAPK. In aged SMC, the level of MAPK
activation experienced a significant rise between 5 min and 1 hour. However, in young
SMC the level of MAPK activation did not demonstrate any significant change during the
same time frame. At 3 hours post stimulation, both young and aged SMC underwent
activation down-regulation. At 5 hours post stimulation, both young and aged SMC
experienced what appeared to be the start of long-term activation up-regulation. At 3 and
5 hours after stimulation, aged SMC again appeared to have a higher level of p42/p44
MAPK activity than young SMC. Overall, the pattern indicated that the p42/p44 MAPK
activation level is higher in aged SMC, both constitutively and post stimulation, with the
exception at 5 min where there was no age differentiation. Additionally, both aged and
young SMC seem to experience what appears to be transient and long-term MAPK
activation in response to FGF-2 stimulation.
This pattern of higher activation level of p42/p44 MAPK in aged SMC led us to
hypothesize that more MAPK activation was present in aged SMC relative to young
SMC at each of the time points. This ratio of activation is illustrated in Figure 4.3, which
expresses the ratio p42/p44 MAPK activation level of aged over young SMC at the
different time points.
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Figure 4.3 Ratio of p42/p44 MAPK activity levels between young and aged SMC. The ratio at each time
point is obtained by the MAPK activity level of aged SMC divided by the MAPK activity level of young
SMC.
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Aged SMC experienced constitutive activation of MAPK that was almost 12
times more than that of the young SMC. However, it was shown that, despite this much
higher level of constitutive activation of MAPK in aged SMC at time zero, 5 minutes post
FGF-2 stimulation witnessed the same level of MAPK activity. This indicated to us that,
once FGF-2 is administered, the rate of activation is more elevated in young SMC within
the first 5 minutes. However, aged SMC's activation level quickly exceeded that of
young SMC at 1 hour, reaching as high as 4-fold relative to young SMC activity level by
3 hours and remaining as high as 3.5-fold by 5 hours post stimulation.
Having examined the absolute level of MAPK activation, we were also interested
in the degree of activation fold increase in young and aged SMC after FGF-2 stimulation.
To examine the fold increase in p42/p44 MAPK activation resulting from FGF-2
stimulation, young and aged phospho-MAPK levels were normalized to the respective
constitutive level at time zero: this normalization is presented in Figure 4.4.
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Figure 4.4 FGF-2 stimulated fold increase of p42/p44L MAPK activation normalized to constitutive
activation level prior to stimulation.
Due to the low constitutive level of p42/p44 MAPK activation in young SMC,
changes in the activation level translated into easily observed fold increase. At 5 minutes
post FGF-2 stimulation, while aged SMC only saw a 5.6-fold increase in activation level,
young SMC saw a 67-fold increase. At the time points following, young SMC also
demonstrated a higher degree of fold increase in MAPK activation.
Noticing the comparable absolute levels of MAPK activation between young and
aged at 5 minutes post FGF-2 stimulation, we normalized the set of data points relative to
the MAPK activation level at this time point. Figure 4.5 illustrates the differentiation in
magnitude and temporal pattern of MAPK activation levels between young and aged
SMC relative to the comparable levels of activation at 5 minutes post FGF-2 stimulation.
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Figure 4.5 FGF-2 stimulated fold increase of p42/p44 MAPK activation normalized to the 5-minute data
point post FGF-2 stimulation.
Figure 4.5 showed how activation at other time points compared to the time point
when the young and aged SMC expressed the same level of p42/p44 MAPK activity.
The activation level of MAPK in young SMC down-regulated soon after 5 minutes,
whereas up-regulation was observed in aged SMC at 1 hour post stimulation. Overall,
the curve of aged SMC maintained a fairly constant gap above the curve of the young
SMC, indicating a consistently higher level of MAPK activity in the aged SMC.
4.4 Discussion
This chapter sought to provide an intracellular signal transduction level
understanding of the age-modulated differentiation of SMC by examining the p42/p44
MAPK transcription and activation levels, constitutively and under FGF-2 stimulation.
The hypothesis which drove this series of experiments postulated that the difference in
the levels of p42/p44 between young and aged SMC reflect the proliferation pattern of
the young and aged SMC.
Our data showed that the amount of MAPK transcribed in SMC is neither up- nor
down-regulate by either the exposure to FGF-2 or the process of aging. At this point, it is
important to note that the Western blotting for MAPK transcription level in this chapter
was conducted under the same conditions as the FGF-2 stimulation assay from Chapter
Two in which we found that age SMC displayed a muted proliferation pattern.
Combining that discovery with the results from this chapter allowed us to drawn the
following conclusion: age-modulated decrease in sensitivity toward FGF-2 stimulation in
SMC cannot result from differentiation in MAPK level. Specifically, the enhanced
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proliferation of young SMC is not a function of up-regulation in MAPK transcription
level, for we have found the level of MAPK to be the same between the young and aged
SMC. Correspondingly, relatively suppressed proliferation of aged SMC is not due to
age-related deficiency in the level of MAPK transcribed.
Having found MAPK level to be unchanged by aging, we looked to activated
MAPK for possible explanation of age-differentiation of proliferation. Our data showed
MAPK activation patterns to be distinct in young and aged SMC. First, aged SMC
experienced a higher level of MAPK activation constitutively. Second, even though aged
and young SMC experienced an equal level of MAPK activation at 5 minutes post FGF-2
stimulation, their subsequent activation pattern diverged. Unlike young SMC, which saw
down-activation of MAPK activity soon after 5 minutes, the level of activation in aged
SMC continued rising and peaked at around 1 hour. In short, aging is associated with
stronger and longer MAPK activation post FGF-2 stimulation, which suggested to us that
relatively stronger mitogenic signals were actually sent downstream in aged SMC, even
though the same amount of stimuli was administered to young and aged SMC. We had
originally hypothesized that a decrease in the level of MAPK activation in aged SMC was
responsible for the age-modulated decrease in SMC proliferation. However, this
hypothesis was shown to be false. The enhanced proliferation of young SMC cannot be
caused by increased MAPK activation, for young SMC actually experienced less
activation. Correspondingly, the muted proliferation of aged SMC cannot be due to age-
related deficiency in the activation of MAPK, for aged SMC actually experienced
heightened MAPK activation.
Combined with the data from the receptor study in Chapter Three, it is clear that
aging has no bearing on the amount of FGF receptor-I and MAPK transcribed. Instead,
aging is associated with an increased number of surface receptor-expressing SMC and an
elevation in the level of MAPK activation. Since surface receptor and MAPK activation
are both important segments of the mitogenic signal transduction pathway, our data
suggest that aging actually leads to what could be seen as heightened activity of these
segments of the pathway-whether they are a higher percentage of the cell population
expressing the receptor or stronger and longer MAPK activation under stimulation.
Viewed in this way, the data from Chapter Two and Chapter Three build upon the same
line of development. However, heightened activity in parts of the mitogenic signal
transduction pathway in aged SMC cannot explain the proliferation profile of aged SMC
observed in Chapter Two. Puzzling as it might seem, there are actually great insights to
be gained, and the implication of this is discussed in the concluding chapter.
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5. CONCLUSION
The motivation behind this thesis research stemmed from the fact that the cellular
and molecular mechanisms responsible for the growth characteristics observed in aged
SMC remain largely unknown.
In studying the effect of aging on SMC proliferation, this thesis arrived at the
interesting and seemingly paradoxical finding that aged SMC demonstrate decreased
proliferation, despite having a higher percentage of receptor-expressing cells and
experiencing elevated MAPK activation. Recall the sequence of events described in
Figure 3.1. Our data pointed out that in aged SMC, more activated MAPK translocate to
the cell nucleus, directly activating transcription factors to start transcribing the cellular
DNA and leading to the end-point biological effect of cell proliferation. Following the
signal strength thus far, one would think aged SMC ought to see more cell proliferation at
the end. However, the data from Chapter Two showed a directly opposite observation.
One can describe this situation using a black box metaphor, where activated
MAPK enter one end of the black box and cell proliferation exits from the other end.
This thesis has demonstrated that, even though aged SMC enter the box with stronger
mitogenic signals, they exit with muted proliferation and a muted stimulation profile.
This seemingly conflicting data led us to conclude that in this black box lies the key to
the age-modulated proliferation and stimulation profile observed in the aged SMC.
Specifically, the next place to look would be aged-related dysfunction in the cell cycle,
which lies downstream of the MAPK pathway.
Our literature search for the effect of aging on cell cycle yielded documented
abnormality in the cell cycle machinery in aged SMC, specifically in cyclin DI and
p27Kipl, both of which are important cell cycle regulatory proteins. Normally, cyclin
DI positively regulates the cell cycle in response to mitogenic stimulation, while
p27Kipl acts as a checkpoint modulating the cell cycle progression. Studies have shown
cyclin DI to be up-regulated after mitogenic stimulation in young and aged SMC but to a
lesser extent in aged SMC. Furthermore, p27Kipl, an inhibitor of proliferation, which is
down-regulated after mitogenic stimulation to allow for proliferation, is not sufficiently
suppressed in aged SMC in response to growth factor stimulation. These specific
dysfunctions of cell cycle machinery in aged SMC are consistent with, and likely to
explain, the muted proliferation profile observed in Chapter Two, which cannot be
overcome by FGF-2 stimulation [12]. In fact, these observations are in agreement with
the cell cycle profile of SMC from human atherosclerotic plaques. It was reported that
p27Kip expression was most consistently observed in advanced atherosclerotic lesions,
and its expression correlated inversely with SMC proliferation and density in advanced
lesions [37, 38].
Assuming cell cycle dysfunctions as reported were indeed true, it is reasonable to
speculate that this deficiency in aged SMC's cell cycle machinery might be doing two
things: First, feeding back to the signal pathway further upstream (receptor expression,
MAPK pathway). Second, attempting to compensate for the cell cycle deficiency, by
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altering the expression and activation level of certain proteins in aged SMC in such a way
as to facilitate potential mitogenesis. This could explain the higher percentage of aged
SMC expressing surface FGF receptor-I under normal growth conditions, for a larger
fraction of aged SMC can readily react to growth factor stimulation. It could also explain
the higher constitutive level of activated MAPK and the elevated level of additional
MAPK activation in aged SMC post FGF stimulation, for this would amplify the
mitogenic cues translocated to the cell nucleus. In another words, age-induced
downstream cell cycle deficiency led to strong mitogenic signals being fed into the
deficient sector of the system, in an attempt to compensate for the decreased proliferation
in aged SMC caused by this deficiency.
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Figure 5.1 System schematic of cellular events associated with the effect of aging on SMC. There are two
types of arrow in this schematic. Arrows with signs signify regulatory relationships with + denoting
positive stimulation and - denoting inhibition. Arrows without signs signify order of events. For every
corresponding pair of arrows between young and aged SMC, thickness denotes the level of intensity.
Figure 5.1 summarizes what we have learned from this thesis research. Aged
SMC, under FGF-2 stimulation, witnessed a relatively higher level of MAPK activation,
which led to a stronger signal entering the cell cycle (represented by the two central,
vertical, thick arrows). However, aging attenuates the positive stimulation of the cell
cycle by cyclin DI and enhances the negative inhibition of the cell cycle by p27KipI due
to the age-related cell cycle dysfunction, thus limiting the proliferation characteristics of
aged SMC (represented by the two curved arrows on the right). In compensation for this
downstream deficiency, it is possible that a positive feedback mechanism enhances
certain aspects of aged SMC upstream (represented by the two curved arrows on the left).
Therefore, even though protein production of FGF receptor-I and MAPK remain
unchanged by aging, there are more aged SMC expressing surface FGF receptor-1, and
there exists a higher basal level of activated MAPK in aged SMC (represented by the two
horizontal arrows on the left). All together, even though the same amount of FGF-2 is
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administered (denoted by arrows of same size coming out of FGF-2), aged SMC
experienced a proliferation profile which is muted compared to that of young SMC
(represented by the pair of arrows entering proliferation).
Placing everything we have learned during this thesis research into the context of
atherosclerotic diseases, we see that indeed age-modulated changes in SMC are indeed a
phenomenon central to providing better prevention and treatment for this disease. This
thesis combines data presented in these chapters to show that decreased proliferation
potential of aged SMC, along with long-term cellular damages and dysfunction, leads to
age-modulated differentiation of SMC. This phenotype of aged SMC contributes to
atherosclerotic plaque instability which characterizes the later stage of atherosclerotic
disease. Because the process of plaque destabilization is often associated with adverse
outcome in patients, the ability to control the age-modulation of SMC would prove to be
life-saving to say the least. This thesis laid groundwork for a better understanding of the
issue of SMC aging in the context of atherosclerotic process. Future researchers can
continue to seek more effective preventive measures and treatment options targeting this
particular issue of aging central to atherosclerotic disease.
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